CRISPR Therapeutics CRSP EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's EPS (diluted)?
- CRISPR Therapeutics (CRSP) reported EPS (diluted) of -$1.28 in Q1 2026.
- How has CRISPR Therapeutics's EPS (diluted) changed year-over-year?
- CRISPR Therapeutics's EPS (diluted) increased by 19.0% year-over-year, from -$1.58 to -$1.28.
- What is the long-term trend for CRISPR Therapeutics's EPS (diluted)?
- Over 2 years (2022 to 2025), CRISPR Therapeutics's EPS (diluted) has grown at a -11.8% compound annual growth rate (CAGR), from -$8.36 to -$6.50.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.